1	Effect of Vitamin D ₃ supplementation vs. dietary-hygienic measures on SARS-COV-2
2	infection rates in hospital workers with 25-hydroxyvitamin D3 [25(OH)D3] levels \geq 20
3	ng/mL
4	
5	Running head: SARS-COV-2 infection and vitamin D ₃
6	Authors: Maria Elena Romero-Ibarguengoitia ^{a,b} , Dalia Gutiérrez-González ^{a,b} , Carlos Cantú-
7	López ^{a,b} , Miguel Angel Sanz-Sánchez ^{b,c} , Arnulfo González-Cantú ^{* b,d} .
8	
9	Author Affiliations:
10	^a Department of Research, Hospital Clínica Nova; San Nicolás de los Garza, N.L., Mexico.
11	^b Universidad de Monterrey, Vicerrectoría de Ciencias de la Salud, Departamento de Ciencias
12	Clínicas, San Pedro Garza García, N.L. Mexico.
13	^c General Management, Hospital Clínica Nova; San Nicolás de los Garza, N.L., Mexico.
14	^d Department of Endocrinology, <i>Hospital Clínica Nova</i> ; San Nicolás de los Garza, N.L., Mexico.
15	
16	Corresponding Author: Arnulfo González-Cantú, Hospital Clínica Nova, Av. del Bosque 139,
17	Cuauhtémoc, 66450 San Nicolás de los Garza, N.L., México. +52- 81- 8865- 5656.
18	drgzzcantu@gmail.com

20 Abstract

21	Background. There is scant information on the effect of supplementation with vitamin D_3 in
22	SARS-COV-2 infection cases when patient 25-hydroxyvitamin D_3 [25(OH)D3] levels are
23	between 20-100ng/mL. Our aim was to evaluate the effect of supplementation with vitamin D_3
24	vs. dietary-hygienic measures on the SARS-COV-2 infection rate in participants with serum
25	25(OH)D ₃ levels \geq 20ng/mL. Methods. We invited hospital workers with 25(OH)D ₃
26	levels between 20-100 ng/mL and no previous SARS-COV-2 infection; they were randomized as
27	follows: treatment options were a) vitamin D ₃ supplementation (52,000 IU monthly, G1) or b)
28	dietary-hygienic measures (G2). We conducted a 3- to 6-month follow-up of SARS-COV-2
29	infections. Participants with $25(OH)D_3$ levels <20 ng/mL were also analyzed. We divided these
30	latter participants depending on whether they were supplemented (G3) or not (G4). Results. We
31	analyzed 198 participants, with an average age of 44.4 (SD 9) years, and 130 (65.7%) were
32	women. G1 had less cases of SARS-COV-2 infection than G2 after a follow-up of 3- to 6-
33	months (p<0.05). There were no differences between G3 and G4 at the 3- and 6-month follow-up
34	cutoff points (p>0.05). Using mixed effect Cox regression analysis in 164 participants that
35	completed six months of follow-up, vitamin D_3 supplementation appeared to act as a protective
36	factor against SARS-COV-2 infection (HR 0.21, p=0.008) in G1 and G2. None of the
37	participants treated with the supplementation doses had serum $25(OH)D_3$ levels > $100ng/mL$.
38	Conclusion. Vitamin D_3 supplementation in participants with $25(OH)D_3$ levels between 20-100
39	ng/mL have a lower rate of SARS-COV-2 infection in comparison with the use of dietary-
40	hygienic measures at six months follow-up.
41	

42 **Keywords:** SARS-COV-2, vitamin D₃, supplementation

43 Introduction

COVID-19 is an infectious disease caused by the newly discovered coronavirus SARS-CoV-2;
its clinical spectrum ranges from asymptomatic infection to critical and fatal illness^{1,2} [1,2]. The
first case was reported in Wuhan, China, in December 2019, while the first case in Latin
America was detected in Brazil in February 2020 ^{3,4} [3,4]. As of March 13, 2022, approximately
48 458,479,635 cases were confirmed, and 3 million deaths were reported worldwide.
Furthermore,10,712,423,741 vaccine doses have been applied⁵ [5].

To date, prevention remains the cornerstone of management to decrease infection rates. In late
2020, the authorization of SARS-CoV-2 emergency vaccines led to partial pandemic control.
However, further studies will be key to obtain clear evidence on its treatment and prevention⁶
[6].

There is controversy on the use of vitamin D_3 supplementation in the prevention of SARS-CoV-2⁷ [7]. A meta-analysis concluded that a low serum 25-hydroxyvitamin D_3 [25(OH) D_3] level was significantly associated with a higher risk of SARS-CoV-2 infection ⁸ [8]. However, there is limited data on the link between SARS-COV-2 infection and vitamin D_3 supplementation in individuals with normal 25(OH) D_3 levels.

59 The rationale for this study was to establish a relationship between vitamin D_3 supplementation

and the incidence of SARS-CoV-2 infection in a prospective study. The target population

61 included health workers at high risk of SARS-COV-2 infection and vitamin D serum values ≥ 20
62 ng/mL.

63 We expected a positive effect of vitamin D supplementation on the immune system (innate and

64 adaptive immunity) 9,10 [9,10], and that the group who underwent supplementation would

65 develop fewer SARS-COV-2 cases.

66	The study aimed to evaluate the effect of vitamin D ₃ supplementation vs. dietary-hygienic
67	measures on the development of SARS-COV-2 infection in participants with serum $25(OH)D_3$
68	\geq 20 ng/mL (primary outcome). Secondarily, we compared a group of hospital workers with
69	serum $25(OH)D_3 < 20$ ng/mL that could not or had not been supplemented with vitamin D ₃ .
70	We hypothesized that low serum vitamin D3 is associated with an increased risk of SARS-COV-
71	2 infection. We believed that we would find a difference in the development of SARS-COV-2 in
72	participants with serum 25(OH)D ₃ \geq 20 ng/mL who received vitamin D ₃ supplementation vs.
73	dietary-hygienic measures ¹¹ [11].
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	

89 Methods and Materials

90 The study was a prospective, quasi-experimental study that followed the CONSORT guidelines²⁵

91 [21]. It included health workers from a hospital in Northern Mexico, the Hospital Clínica Nova

92 (HCN), at a northern latitude of 25°45' and western latitude of 100°17`. This hospital was

93 converted to a COVID-19 Hospital in March 2020. Participant recruitment began in May-August

94 2020, when the initial baseline serum vitamin D level was obtained. Participant follow-up

95 continued from August 2020 through January 2021.

The study was conducted per The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments in humans. It was also approved by the local IRB of the *Universidad de Monterrey* (Ref. 30062020-a-CN-CI) and registered with the clinical trial number NCT04810949 (first released 23/03/2021). Due to the study's nature, an informed consent form was signed by each participant, and two witnesses. The author, AGC, enrolled the participants and assigned them to each intervention.

102 The inclusion criteria were age between 18 and 65 years old, both genders, absence of infection 103 by SARS-COV-2, influenza H1N1, influenza A or B at the time of serum vitamin D_3 104 determination, absence of infection at any site (bacteria or fungi), and participants had to be 105 hospital workers at the HCN. In addition, participants were excluded if their serum 25(OH) D_3 106 was >100 ng/mL, if they had previously received supplements containing vitamin D_3 , and if they 107 were pregnant.

108 Individuals were invited to participate in the study after signing the consent form. They were 109 directed to the laboratory to provide serum samples to determine their levels of $25(OH)D_3$. We 110 used the Elecsys total vitamin D test with COBAS 6000 (e601) equipment (Wiesbaden 111 Germany). The CV was 4.1%, the analytic specificity for $25(OH)D_3$ was 100%, and the analytic

sensibility was established at 4.01ng/mL. Calibration of the equipment was performed by the
laboratory staff every time there was a change in the lot, and the calibration curve factor was 1
(goal 0.8- 1.2).

115

116 Based on the results, we classified participants into four groups. The first and second groups had 117 $25(OH)D_3 > 20$ ng/mL and they were randomized in a 1:1 ratio; the participants had two 118 treatment options: the first, was supplementation with vitamin D_3 52,000 IU in a single dose, 119 monthly, for three months (13 tablets of 4,000 UI, G1). The total dose is based on the Endocrine Society's Guidelines^{26,27} [26,27]: however, we decided to administer it every month instead of a 120 daily, since some of this frequency's benefits have been discussed elsewere²⁸[25]. The second 121 122 option was treatment based on dietary-hygienic measures (G2), such as sun exposure for at least 123 10 minutes per day between 10:00-18:00 hrs., and foods that were rich in vitamin D_3 and D_2 (fish, meat, eggs, milk, mushrooms, and, almonds)^{29,30}[29,30]. 124

125 The third and fourth groups had $25(OH)D_3$ levels <20 ng/mL. These groups were not part of the 126 randomization process, since we considered that all subjects with vitamin $D_3 < 20$ mL should receive vitamin D_3 supplementation³¹ [31], and they were referred to their personal primary care 127 128 physician (different primary care physician) for treatment and follow-up (G3). Nevertheless, a 129 certain number of participants decided, of their own volition, not to receive vitamin D_3 130 supplementation (G4), but since they were health workers and had a medical record from the same hospital where the study was conducted, we could still follow them over time. Our 131 132 secondary aim was to also determine the incidence of SARS-COV-2 infection in this group. We, therefore, had 4 groups for comparisons. 133

134 Variables obtained from the medical record were age, gender, occupation, diabetes mellitus,135 hypertension, allergies, asthma, smoking history, previous hospitalizations, and BMI.

136 The participants were monitored monthly during follow-up, every month by telephone, and every

137 3 months in a face-to-face interview. We inquired on COVID-19 symptoms (myalgias,

138 hyposmia, cough, malaise and fatigue, nasal congestion, fever, diarrhea, thoracic pain, shaking

139 chills, nausea, and vomiting), and whether they had been diagnosed with SARS-COV-2 infection

140 by serologic or swab tests (PCR). Also, every month patients were asked if they had been

141 consuming food with vitamin D_3 or D_2 using a 24h food recall questionary. Serum 25(OH) D_3

142 was measured at baseline and after three months of follow-up.

The relative risks that could be present in the different groups were increased serum vitamin D
levels (> 100ng /ml) in G1 and decreased vitamin D serum levels < 20ng/mL in G2. The risks in
G3 and G4 could not be controlled by the research group.

146 The relative risks that could be present in the different groups were an increase in vitamin D 147 serum levels > 100ng /ml in G1, and decreased vitamin D serum levels < 20ng/mL in G2. The 148 risk in G3 and G4 could not be controlled by the research group.

149

150 Statistical analysis

Two researchers reviewed the quality control of the database and anonymized it. Normality assumption was evaluated with the Shapiro Wilk test and frequency histograms. Descriptive statistics such as the mean, the standard deviation for quantitative variables, frequencies, and percentages for categorical variables, were computed. Chi-square tests and ANOVA were used to compare the categorical and quantitative data between groups. Kaplan-Meier curves and the Log-rank test were used to evaluate the difference in SARS-COV-2 infection between groups.

157	We conducted a mixed effect Cox regression analysis in the groups with $25(OH)D_3 \ge 20 \text{ ng/mL}$
158	and <20 ng/mL, in which the dependent variable was SARS-COV-2 infection at six months. The
159	covariates computed in the model were vitamin D_3 supplementation, age, and gender. The
160	seasonal variation was a random effect. Missing data were handled by complete case analysis.
161	For the simple randomization, we used random number generation with a binomial distribution,
162	and a probability of 50%. The author, AGC, generated the randomization sequence.
163	The statistical programs used were SPSS version 25 (IBM, USA) and R software version 4.0.3
164	(R Core Team, Vienna Austria). The analysis was two-tailed. A p-value < 0.05 was considered
165	statistically significant. The sample size included all hospital workers that agreed to provide
166	serum samples for $25(OH)D_3$ testing.
167	
168	
169	
170	
171	
172	
173	
174	
175	
176	
177	
178	
179	

180 Results

- 181 Initially, 205 hospital workers were considered for the study; five had to be excluded because
- they had previously contracted SARS-COV-2, before the study started. Additionally, two
- individuals in the G1 and G2 withdrew their consent to participate.
- 184 In the end, 198 participants were analyzed. These participants were distributed in four groups
- based on their 25(OH)D₃ levels and the type of treatment administered. Group 1 (G1) included
- participants with $25(OH)D_3$ level ≥ 20 mL plus supplementation (52,000IU/month) (n=43).
- 187 Group 2 (G2) consisted of participants with $25(OH)D_3$ level ≥ 20 ng/mL managed with dietary-
- hygienic measures (n=42). Group 3 (G3) had participants with serum 25(OH)D₃ <20ng/mL plus
- supplementation (90,000IU/month, average dose provided by their treating physician) (n=28).
- 190 Finally, group 4 (G4) included participants with $25(OH)D_3 < 20ng/mL$, without supplementation
- 191 (n=85).
- 192

The mean (SD) age in the four groups was 44.4 (9.1) years (p>0.05), with no difference between
groups, and 130 were female (65.7%). The three most frequent professions in all the groups
were: physician, nurses, and administrative workers, and no difference was established among
G1-G4 (p>0.05). There were also no differences in terms of smoking history, Body Mass Index
(BMI), allergies, Type 2 diabetes, hypertension, and asthma (p>0.05). Demographic data and
medical history of the groups are described in Table 1.

- 199
- 200 The mean (SD) serum baseline $25(OH)D_3$ levels reported per group were: 27.1 (6.7) ng/mL in
- 201 G1, 26.6 (5.5) ng/mL in G2, 15.4 (3.4) ng/mL in G3, and 14.9 (3.1) ng/mL in G4, p<0.001.
- 202 Serum levels of 25(OH)D₃ were again measured after three months of follow-up. The values

were as follows: G1 33.8 (7.1) ng/mL, G2 22.4 (6.9) ng/mL, G3 38.2 (8.5) ng/mL and G4 22.1
(5.8) ng/mL, p<0.001.

205

At the 3-month cutoff, 51 (25.8%) of the 198 workers had developed SARS-COV-2 infection
(naïve variant). The distribution of cases by groups was: G2 14 (33%) and G1 3 (7%), p= 0.002;
G4 27 (32%) and G3 7 (25%), p>0.05. When comparing between the four groups there was a
statistical difference, p=0.017.

210

211 One hundred eighty-seven (187) individuals were followed for four months; of these, 56 (29.4%) 212 developed SARS-COV-2 infection (naïve variant). The proportion of SARS-COV-2 infection 213 cases by groups was: G2 14 (34%) and G1 6 (14%), p= 0.002; G4 29 (38%), and G3 7 (26%), p 214 = 0.04. When comparing between the four groups there was a statistical difference, p=0.041 215 Additionally, we studied 167 workers that completed a 6-month follow-up. Not all participants 216 completed this 6-month follow-up because they were recruited at a later date, the SARS-COV-2 217 vaccination campaign had begun, and we considered that vaccination could affect our results; we 218 therefore completed our study follow-up, and they were not included in this timeline analysis. 219 However, during that period, 56 (33.5%) developed Covid-19 (naïve variant). The number of 220 cases by group was as follows: G2 13 (39%) and G1 5 (13%), p<0.001; G4 29 (40%) and G3 9 221 (37%), p >0.05. When comparing between the four groups there was statistical difference, 222 p=0.031. Figure 1 shows comparisons between G1 vs. G2 and G3 vs G4. The Nursing 223 Department had the highest proportion of SARS-COV-2 infections, although no statistical 224 difference between groups was detected (p > 0.05). The most frequently reported symptoms were 225 myalgias and fatigue. A total of 8 (14%) participants were hospitalized during the study, with no

- statistical difference between groups (p>0.05). Only one worker in the G4 group required
- intubation. There were no deaths in the study. Data on the SARS-COV-2 infections during the 6-
- 228 month follow-up is presented in Table 2.
- 229 We conducted a mixed effect Cox regression analysis with the participants who were followed
- for six months (n=164). The final covariates computed in the model were vitamin D_3
- supplementation, age, and gender. The seasonal variation was a random effect. In the Group \geq
- 232 $20ng/mL 25(OH)D_3$, the resulting HR was 0.21 (SE 0.58, p= 0.008) for vitamin D_3
- 233 supplementation; age, 0.97 (SE 0.26, p=0.25); and gender, 0.85 (SE 0.49, p=0.76). In the Group
- 234 < 20 mL 25(OH)D₃, the HR was 1.15 (SE 00.39, p= 0.72) for vitamin D₃ supplementation;
- 235 age, 1.001 (SE 0.02, p=0.94); and gender, 0.52 (SE 0.48, p=0.18). Other covariates that were
- explored were BMI, Type 2 diabetes, and hypertension, but they were not statistically
- significant, so they were eliminated from the final models.
- In the G1 and G3 groups that were supplemented with 52,000 IU/month and 90,000IU for three
- months, respectively, none of the participants had $25(OH)D_3$ levels >100 ng/mL and no adverse
- events were reported.
- 241
- 242
- 243
- 244
- 245
- 246
- 247
- 248

249 Discussion

250 This study demonstrated that vitamin D_3 supplementation for three months led to a decrease in

- 251 the rate of SARS-COV-2 infection in the group of participants with $25(OH)D_3$ levels ≥ 20 ng/mL
- throughout the 3–6-month follow-up when compared with dietary-hygienic measures.
- In this study, participants with 25(OH)D₃ levels < 20 ng/mL had a higher rate of SARS-COV-2
- infection; however, upon comparison of groups (G3 and G4), the supplemented group had less
- 255 frequent SARS-COV-2 infections at four months of follow-up but not at six months.

256

257 Previous studies, including a metanalysis, revealed an association of low serum 25(OH)D₃ levels with SARS-COV-2 infection^{8,12}[8,12]. Another study reported a correlation of this 258 259 deficiency with an aging population, aside from associated comorbidities such as diabetes mellitus, hypertension, or obesity^{12,13} [12,13]. This suggests that there is an inverse relation 260 261 between SARS-COV-2 infection and $25(OH)D_3$ levels. As mentioned previously, we did find an 262 association between low levels of 25(OH)D₃ and SARS-COV-2 infection; however, when we 263 evaluated the comorbidities, we did not find a difference in participants with comorbidities. 264 Thus, the most important predictor of infection in the regression models was the supplementation 265 with vitamin D_3 and low $25(OH)D_3$ values.

266

A study conducted in Barcelona demonstrated that participants that had previously received vitamin D for four months were at a decreased risk of acquiring SARS-COV-2 infection (HR = 0.95, CI 0.91-0.98), but this was not applicable in individuals on calcifediol¹⁴ [14]. A previous clinical trial conducted in Mexico City included health workers who were randomized to receive either 4000 IU of vitamin D₃ for 30 days or placebo and were followed for 45 days. The results

showed that independently of the baseline $25(OH)D_3$ (that in the study was mostly deficient), the supplemented group had a lower incidence of SARS-COV-2 infection¹⁵ [15].

A study conducted in Veteran patients in the US Defense Department health system, showed an

275 inverse dose-response relationship between continuously increasing 25(OH)D concentrations

276 (from 15 to 60 ng/mL with supplementation), and a parallel decreased probability of requiring

277 COVID-19-related hospitalization¹⁶ [16].

278

As previously stated, our study supports the importance of supplementation. Nevertheless, there is still a lack of information to be obtained in clinical trials on SARS-COV-2 management, and on the potential benefit of supplementation with vitamin D_3 in participants with $25(OH)D3 \ge 20$ ng/mL to decrease SARS-COV-2 infection risk; therein lies the value of our study in which we also evaluated the effect in this group of participants in a prospectively manner.

284

285 We observed that in our group of participants who followed dietary-hygienic measures, their 286 $25(OH)D_3$ levels had decreased when measured a second time. This may result from the 287 difficulty among the participants to closely adhere to the recommendations provided by the 288 physician, such as sun exposure, work hours, and diet. Further, it is important to note that the 289 second measurement of $25(OH)D_3$ was obtained in the winter season. These factors could 290 explain the increased number of cases of SARS-COV-2 infection and underscore the usefulness 291 of supplementation in the population during this time of the year. Our regression model that 292 adjusted the seasonal variation, reinforce the importance of supplementation.

293

13

294 Since there is evidence of a greater risk of acquiring a SARS-COV-2 infection and an increase in its severity among participants with $25(OH)D_3$ levels $<20 \text{ ng/mL}^{8,17-19}[8,15,17]$, we considered 295 296 it would not be ethical to randomize treatment in these groups of participants. They were referred 297 to the primary care physician to initiate supplementation. Unfortunately, despite the treatment 298 options and recommendations, some participants decided not to follow them. However, the 299 supplemented group had a lower incidence of SARS-COV-2 at four months of follow-up but not 300 at six months. We believe that there was an important effect of 3-month supplementation but that 301 was not sustained for six months, so future studies must be conducted were a sustained 302 supplementation is evaluated. 303 From a mechanistic point of view, vitamin D status could also be an index of nitric oxide 304 concentrations induced by solar UVA rays and these may act in concert to potentially prevent the COVID-19-dependent cytokine storm and induced inflammation^{20,21} [20,21]. Also, vitamin D 305 306 could protect against viral infection through the innate immune response. The induction of 307 cathelicidin and defensing can block viral entry to the cell and suppress viral replication. Another 308 mechanism is by promoting autophagy of the virus, expressing autophagy marker LC3, 309 downregulating the mTOR pathway, promoting Beclin 1and PI3KC3, and stimulating the 310 formation of autophagosomes to indirectly facilitate viral clearance. Therefore, vitamin D could 311 have an important role in maintaining the balance between autophagy and apoptosis, and thus maximize the antiviral response to infection 10,22 [10,18]. 312 313 Vitamin D is also a regulator of the adaptive immune response by inducing regulatory T cells 314 that are critical to the induction of immune tolerance, and play a role in preventing the cytokine

storm associated with severe respiratory disease caused by viral infections. Vitamin D, via its

active metabolite 1,25(OH)₂D, limits the maturation of dendritic cells, and hence, their ability to

present antigen to T cells, and change the T cell profile from the proinflammatory Th1 and Th17
to Th2 and T regulatory subsets, that inhibit the proinflammatory processes¹⁰ [10].

319

320 Activation of the vitamin D receptor could play a modulatory role to the host responses in the

321 acute respiratory distress syndrome by decreasing cytokines, producing a shift toward amplified

322 adaptive Th2 immune responses, regulating the renin-angiotensin-bradykinin system, modulating

323 neutrophil activity, and maintaining the integrity of the pulmonary epithelial barrier, thus

324 promoting epithelial repair, and decreasing the coagulability and prothrombotic tendency

associated with SARS-COV-2 infection $^{22-24}$ [18-20].

326 One of our study's limitations is the sample size in each group; however, using a formula for the 327 proportion difference between independent groups of 26%, we achieved a power of 86%. Also, some participants did not complete their follow-up at 4- and 6-months because of SARS-COV-2 328 329 vaccination. We decided to discontinue the study once patients were vaccinated since it could 330 affect our primary outcome. Finally, the study was conducted in only one center and mostly in 331 the winter, so a multicenter study conducted during all seasons is required in the future, and with 332 a greater sample size to confirm the risks and benefits of supplementation in participants with 333 $25(OH)D_3$ levels <20 ng/mL, in terms of the acquisition of SARS-COV-2 infections.

334

The risks of the protocol were minimal since the supplementation of vitamin D_3 at doses of 52,000 units per month is not related to any adverse event. Vitamin D hypervitaminosis occurs when serum levels are > 100ng / ml. The administered supplementation dose had a very low risk of causing hypervitaminosis D. Nevertheless, participants' serum levels were monitored at three months as a security measure. Another risk of the study was the possibility of an allergic reaction

to any component of the vitamin D₃ presentation formula, but none of the participants developed
this condition.

342 Acknowledgments

- 343 We are grateful to Rosalinda González Facio, Laura Patricia Montelongo, and Gerardo Del Río
- 344 Parra for their assistance in participant follow-up during the trial, and their review of medical
- 345 records. Likewise, we appreciate the Nursing Department's coordination of appointments.

346 Author Contribution:

- 347 Conceptualization: MERI, AGC, DGG, and MASS. Formal analysis: MERI, AGC, DGG, and
- 348 CCG. Investigation: MERI, AGC, DGG, MASS, and CCG. Resources: MASS, Writing -
- 349 original draft: MERI, AGC, DGG, MASS, and CCG. Writing review and editing: MERI,
- 350 AGC. Project administration: MERI, DGG, and MASS. Supervision: MERI, AGC, and MASS.
- 351 Funding acquisition: MASS. All authors contributed to this article and approved the submitted
- 352 version.

353 Competing interests:

354 The author(s) have no conflicts of interest to declare.

355 Data Availability:

- 356 Data are available upon reasonable request to the corresponding author
- 357 Funding:
- 358 This research received private funding from the hospital. No specific grant was awarded from
- any funding agency in the public, commercial, or non-profit sectors.

360 Ethics Statement:

- 361 This research project was approved by the local IRB of the Universidad de Monterrey (Ref.
- 362 30062020-a-CN-CI). An informed consent form was obtained from each participant.

363 Disclosure

364 The authors have no potential conflicts of interest associated with this study.

- 365 Author Approval: all authors read an approved the final version of the manuscript.
- **Protocol access:** This study protocol can be reviewed in Clinicaltrials.gov.
- 367

368 **References**.

- 1. Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel
- 370 coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* **395**, 507–513 (2020).
- 371 2. Jiang, F. *et al.* Review of the Clinical Characteristics of Coronavirus Disease 2019
- 372 (COVID-19). J. Gen. Intern. Med. 35, 1545–1549 (2020).
- 373 3. Lopez Santi, R. *et al.* Impact of the Pandemic on NonInfected Cardiometabolic Patients:
- A Survey in Countries of Latin America—Rationale and Design of the CorCOVID LATAM
 Study. *CJC Open* 2, 671–677 (2020).
- 376 4. Spiteri, G. *et al.* First cases of coronavirus disease 2019 (COVID-19) in the WHO
- European Region, 24 January to 21 February 2020. *Eurosurveillance* 25, (2020).
- 378 5. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int.
- 379 6. Mattoli, S. Filling the Gap Until Full Vaccine Deployment in the War on Coronavirus
 380 Disease-19. *Infect. Dis. Ther.* 10, 27–34 (2021).
- 381 7. Griffin, G. *et al.* Perspective: Vitamin D supplementation prevents rickets and acute
- respiratory infections when given as daily maintenance but not as intermittent bolus: implications
 for COVID-19. *Clin. Med.* 21, e144–e149 (2021).
- 384 8. Teshome, A., Adane, A., Girma, B. & Mekonnen, Z. A. The Impact of Vitamin D Level
 385 on COVID-19 Infection: Systematic Review and Meta-Analysis. *Front. Public Health* 9, 624559
 386 (2021).
- 387 9. Džopalić, T., Božić-Nedeljković, B. & Jurišić, V. The role of vitamin A and vitamin D in
 388 the modulation of the immune response with focus on innate lymphoid cells. *Cent. Eur. J.*
- 389 *Immunol.* **46**, 264–269 (2021).
- Bilezikian, J. P. *et al.* MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-*19. Eur. J. Endocrinol.* 183, R133–R147 (2020).
- 392 11. Office of Dietary Supplements Vitamin D. https://ods.od.nih.gov/factsheets/VitaminD 393 Consumer/.
- 12. Ilie, P. C., Stefanescu, S. & Smith, L. The role of vitamin D in the prevention of
- 395 coronavirus disease 2019 infection and mortality. *Aging Clin. Exp. Res.* **32**, 1195–1198 (2020).
- 396 13. Ejaz, H. *et al.* COVID-19 and comorbidities: Deleterious impact on infected patients. *J.*397 *Infect. Public Health* 13, 1833–1839 (2020).
- 14. Oristrell, J. *et al.* Vitamin D supplementation and COVID-19 risk: a population-based,
- 399 cohort study. J. Endocrinol. Invest. 45, 167–179 (2022).
- 400 15. Villasis-Keever, M. A. *et al.* Efficacy and Safety of Vitamin D Supplementation to
- 401 Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial. Arch. Med.
- 402 *Res.* **53**, 423–430 (2022).

- 403 16. Seal, K. H. et al. Association of Vitamin D Status and COVID-19-Related
- 404 Hospitalization and Mortality. J. Gen. Intern. Med. 37, 853–861 (2022).
- 405 17. Dror, A. A. *et al.* Pre-infection 25-hydroxyvitamin D3 levels and association with
 406 severity of COVID-19 illness. *PLOS ONE* 17, e0263069 (2022).
- 18. Demir, M., Demir, F. & Aygun, H. Vitamin D deficiency is associated with COVID-19
 positivity and severity of the disease. *J. Med. Virol.* 93, 2992–2999 (2021).
- 409 19. Chiodini, I. *et al.* Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical
- 410 Outcomes. *Front. Public Health* **9**, 736665 (2021).
- 411 20. Cherrie, M. et al. Ultraviolet A radiation and COVID 19 deaths in the USA with
- 412 replication studies in England and Italy*. *Br. J. Dermatol.* **185**, 363–370 (2021).
- 413 21. Gorman, S. & Weller, R. B. Investigating the Potential for Ultraviolet Light to Modulate
- 414 Morbidity and Mortality From COVID-19: A Narrative Review and Update. *Front. Cardiovasc.*415 *Med.* 7, 616527 (2020).
- 416 22. Loucera, C. *et al.* Real world evidence of calcifediol or vitamin D prescription and
- 417 mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients. *Sci.*
- **418** *Rep.* **11**, 23380 (2021).
- 419 23. Quesada-Gomez, J. M., Entrenas-Castillo, M. & Bouillon, R. Vitamin D receptor
- 420 stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus
- 421 SARS-CoV-2 infections: Revised Ms SBMB 2020_166. *J. Steroid Biochem. Mol. Biol.* 202, 105719 (2020).
- 423 24. Martinez Moreno, J. M. *et al.* Vitamin D modulates tissue factor and protease □ activated 424 receptor 2 expression in vascular smooth muscle cells. *FASEB J.* **30**, 1367–1376 (2016).
- 425 25. Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group. CONSORT 2010
- 426 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ* **340**, c332– 427 c332 (2010).
- 428 26. Holick, M. F. Vitamin D Deficiency. N. Engl. J. Med. 357, 266–281 (2007).
- 429 27. Holick, M. F. et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an
- 430 Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 96, 1911–1930
 431 (2011).
- 432 28. De Niet, S. *et al.* A Randomized Study to Compare a Monthly to a Daily Administration
 433 of Vitamin D3 Supplementation. *Nutrients* 10, 659 (2018).
- 434 29. Crowe, F. L. et al. Plasma concentrations of 25-hydroxyvitamin D in meat eaters, fish
- eaters, vegetarians and vegans: results from the EPIC–Oxford study. *Public Health Nutr.* 14,
 340–346 (2011).
- 437 30. Bouillon, R., Verlinden, L. & Verstuyf, A. Is Vitamin D2 Really Bioequivalent to 438 Vitamin D3? *Endocrinology* **157**, 3384–3387 (2016).
- 439 31. Szarpak, L. *et al.* A systematic review and meta-analysis of effect of vitamin D levels on 440 the incidence of COVID-19. *Cardiol. J.* **28**, 647–654 (2021).
- 441
- 442
- 443
- 444

445 Figure legends. SARS-COV-2-free survival

- 446 Kaplan Meier curves of the SARS-CoV-2 infection rate during the six-month follow-up. The
- 447 images compare the 4 groups according to their baseline vitamin status and vitamin D3. Figure
- 448 A shows the group with serum $25(OH)D3 \ge 20 \text{ ng/mL}$. Figure B shows $25(OH)D3 \le 20 \text{ ng/mL}$
- 449 The lowest rate of SARS-COV-2 infection occurred in the group with vitamin D > 20 mL plus
- 450 supplementation for three months, 52000IU per month.

451 Tables

Groups n=198	G1	G2	p-	G3	G4		
	n= 43	n=42	value	n= 28	n= 85	p-value*	
Female	26 (60)	19 (45)	>0.05	20 (71)	65 (76)	>0.05	
	Profession						
Physician (%)	15 (35)	16 (38)		7(25)	23(27)		
Nurse (%)	19(44)	15(36)		13(46)	39(46)		
Dentist (%)	1(2)	2(5)		1(4)	7(8)		
Mantenance	2(5)	3(7)		0	1(1)		
(%)			>0.05			>0.05	
Administrative	5(12)	1(2)		4(14)	9(11)		
(%)			_			_	
Nutritionist (%)	0	3(7)		2(7)	2(2)		
Other (%)	1(2)	2(5)		1(4)	4(5)		
	Medical History						
Tobacco(%)	1(2)	4(10)	>0.05	2(7)	3(4)	>0.05	
BMI (SD)	26.4(5.1)	26.3(3.5)	>0.05	27.8(2.1)	28.2(4.5)	>0.05	
Type 2 Diabetes (%)	5(11)	1(2)	>0.05	2(7)	6(7)	>0.05	
Allergies (%)	7(16)	7(17)	>0.05	7(25)	20(24)	>0.05	
Hypertension (%)	6(14)	3(7.5)	>0.05	5(18)	11(13)	>0.05	
Asthma (%)	2(5)	2(5)	>0.05	0	0		

452 Table1. Demographics and Medical History

*Chi-square test was performed for between-group comparisons. A p-value ≤ 0.05 was considered statistically significant. Parentheses represent frequency or standard deviation. Abbreviation: SD: standard deviation; BMI: body mass index; G1: 25(OH)D3 \geq 20 ng/mL with

- 456 supplementation; G2: 25(OH)D3 >20 ng/mL without supplementation; G3: 25(OH)D3 <20
- 457 ng/mL with supplementation; G4 25(OH)D3 <20 ng/mL without supplementation.
- 458
- 459 Table 2. SARS-COV-2 infection at 6-month follow-up

n=167	G1	G2	p-	G3	G4	
						p-value
	(n=38)	(n=33)	value	(n=24)	(n=72)	
SARS-COV-2	5 (13)	13 (39)	0.01	9 (37)	29 (40)	>0.05
Physician (%)	2(15)	3(23)	>0.05	2(22)	5(17)	>0.05
Nurse(%)	2(11)	8(61)	0.003	6(67)	17(59)	>0.05
Dentist (%)	0	0		0	3(10)	
Administrative (%)	1(20)	1(100)	>0.05	0	3(10)	
Nutritionist (%)	0	1(33.)		1(11)	1(3)	>0.05
		SARS-COV-2 a	associate	d symptoms		
Dry cough (%)	0(0)	0(0)		2(22)	5(17)	>0.05
Fatigue (%)	2(40%)	1(7.7%)	>0.05	4(44)	4(14)	0.049
Sore throat (%)	1(20%)	0		1(11)	5(17)	>0.05
Nasal congestion	1(20%)	1(7.7%)	>0.05	0	2(7)	
(%)						
Fever (%)	1(20%)	2(15.4%)	>0.05	1(11)	2(7)	>0.05
Myalgias (%)	4(80)	2(8)	0.009	4(44)	4(13.8%)	0.049
Diarrhea (%)	1(20)	1(8)	>0.05	1(11)	0	
Chest pain (%)	1(20)	0		0	2(7)	
Shaking chills (%)	1(20)	0		1(11)	0	
Nausea (%)	1(20)	0		0	0	
Hyposmia (%)	0	1(8)			0	
Hospitalizations (%)	2 (40)	1 (8)	>0.05	3 (33)	2 (7)	0.04
Intubations (%)	0 (0)	0 (0)		0	1 (3)	
Reservoir mask (%)	1(20)	0(0)		0	0	
Oxygen via nasal prongs (%)	0 (0)	0 (0)		0	1 (3)	
Pneumonia (%)	3(60)	1(7.7)	0.017	1(11)	2(7)	>0.05

460 A p-value ≤ 0.05 was considered statistically significant. Abbreviation: SD: standard deviation; G1: 461 $25(OH)D3 \geq 20$ ng/mL with supplementation; G2: 25(OH)D3 D ≥ 20 ng/mL without supplementation;

G3: 25(OH)D3 <20 ng/mL with supplementation; G4: 25(OH)D3 <20 ng/mL without supplementation.

463 Parentheses represent frequency or standard deviation

